SavedAdd your journal

Journals / Güncel Retina Dergisi / 2018 / Cilt: 2 - Sayı: 4

Use of Oral Steroids and Immunosuppressant / Immunomodulators in the Treatment of Behcet’s Disease-Related Uveitis

Behçet Hastalığına Bağlı Üveitin Tedavisinde Oral Steroidler ve İmmünsupresan/İmmünmodülatörlerin Kullanımı

MUHAMMED BATUR
Muhammet Derda ÖZER
SEREK TEKİN
Pages
343–347
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

But unfortunately refractory uveitis exacerbations could be seen despite the conventional immunosuppressive treatment.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Behçet’s disease is a multisystemic inflammatory disease of unknown ethiology.
📊
Key Findings & Data:Unpredictable severe inflammatory ocular exacerbations are usual during the course of disease and if these acute attacks did not treated in a fast and effective manner, permanent ocular complications would be inevitable.
💡
Conclusion & Impact:But unfortunately refractory uveitis exacerbations could be seen despite the conventional immunosuppressive treatment.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Behçet’s disease is a multisystemic inflammatory disease of unknown ethiology. Unpredictable severe inflammatory ocular exacerbations are usual during the course of disease and if these acute attacks did not treated in a fast and effective manner, permanent ocular complications would be inevitable. Immune suppressive drugs combined with high-dose systemic corticosteroids are used in resistant uveitis attacks with severe posterior segment involvement, while topical therapy is sufficient only in cases with anterior segment involvement. But unfortunately refractory uveitis exacerbations could be seen despite the conventional immunosuppressive treatment.

Özet

Behçet hastalığı sebebi bilinmeyen kronik, multisistemik enflamatuar bir hastalıktır. Hastalığın seyri sırasında öngörülemeyen ciddi enflamatuar ataklar gözlenmektedir ve arka segmenti etkileyen ciddi ataklar hızlı ve etkili tedavilerle sakinleştirilemezse kalıcı oküler hasar kaçınılmazdır. Sadece ön segment tutulumu olan olgularda topikal tedavi yeterli olurken, ciddi arka segment tutulumu olan dirençli üveit ataklarında, yüksek doz sistemik kortikosteroid ile kombine immünsüpresif ilaçlar kullanılır. Fakat konvansiyonel immünsüpresif ilaçlara rağmen dirençli üveit atakları gözlenebilmektedir.

🔖

Cite This Article

BATUR, M., ÖZER, M. D., TEKİN, S. (2018). Use of Oral Steroids and Immunosuppressant / Immunomodulators in the Treatment of Behcet’s Disease-Related Uveitis. Güncel Retina Dergisi, Cilt: 2 - Sayı: 4, 343–347. https://ajindex.com/articles/190652

References (14)

  1. Mishima S, Masuda K, Izawa Y, Mochizuki M, Namba K. Behçet disiease in Japan: ophthalmologic aspects. Trans Am Ophthalmol Soc. 1979;77:225-79
  2. Hatemi G, Silman A, Bang D, Bodaghi B, et al. EULAR recommendations for the management of Behçet disease. Ann Rheum Dis. 2008;67(12):1656-62.
  3. Yazici H, Pazarli H, Barnes CG, Tüzün Y, Ozyazgan Y, Silman A, et al. A controlled trial of azathioprine in Behçet’s syndrome. N Engl J Med. 1990;322(5):281-5.
  4. Benezra D, Cohen E. Treatment and visual prognosis in Behçet’s disease. Br J Ophthalmol. 1986;70(8):589-92
  5. Chajek T, Fainaru M. Behçet’s disease: Report of 41 cases and review of the literature. Medicine. 1975;54(3):179-96
  6. Mamo JG, Baghdassarian A. Behçet’s disease: A report of 28 cases. Arch Ophthalmol. 1964;71:4-14.
  7. Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Huseyin Altunbas H, Urgancioglu M. Uveitis in Behçet’s disease: an analysis of 880 patients. Am J Ophthalmol. 2004;138(3):373–80
  8. Reed BJ, Morse LS, Schwab IR. High dose intravenous pulse methylprednisolone hemisuccinated in acute Behçet’s retinitis. Am J Ophthalmol. 1998;125(3):409-11
  9. Kotter I, Deuter C, Stubiger N, Zierhut M. Interferon-a (IFN-a) application versus tumor necrosis factor-a antagonism for ocular Behçet’s disease: focusing more on IFN. J Rheumatol 2005;32(8):1633. Saadoun D, Wechsler B, Terrada C, Hajage D, Le Thi Huong D, Resche- Rigon M. Azathioprine in severe uveitis of Behçet’s disease. Arthritis Care Res (Hoboken). 2010;62(12):1733–8. Santamaria J. Steroidal agents. The systemic and ocular complications. Ocular Inflamation Ther. 1988;1:19-25.
  10. Markomichelakis N, Delicha E, Masselos S, Fragiadaki K, Kaklamanis P, Sfikakis PP. A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behçet’s disease: a comperative 4 week study. Rheumatology. 2011;50(3):593-7
  11. Fabiani C, Vitale A, Emmi G, Lopalco G, Vannozzi L, Guerriero S, et al. Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet’s disease-related uveitis: a multicenter retrospective observational study. Clin Rheumatol. 2017;36(1):191-7.
  12. Ozyazgan Y, Yurdakul S, Yazici H, Tüzün B, Işçimen A, Tüzün Y, et al. Low dose cyclosporine versus pulsed cyclophosphamide in Behçet’s syndrome: a single masked trial. Br J Ophthalmol. 1992;76:241-3
  13. Masuda K, Nakajima A, Urayama A, Nakae K, Kogure M, Inaba G. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet’s disease. Lancet 1989;1(8647):1093-6.
  14. Allison AC, Eugui EM. Immu